舌鳞状细胞癌组织中硫氧还蛋白和硫氧还蛋白还原酶-1的表达及其意义

doi:10.3969/j.issn.1004-616x.2018.02.002

癌变·畸变·突变 ›› 2018, Vol. 30 ›› Issue (2): 87-91.doi: 10.3969/j.issn.1004-616x.2018.02.002

舌鳞状细胞癌组织中硫氧还蛋白和硫氧还蛋白还原酶-1的表达及其意义

李杨^1,2, 邢龙^3,4, MOHAMMED H^1,2, 马小龙^1,2, 谢富强^1,2, 冯正虎^3,4, 车银富¹

1. 兰州大学口腔医学院, 甘肃兰州 730000;
2. 兰州大学第二医院, 甘肃兰州 730000;
3. 西北民族大学口腔医学国家民委重点实验室, 甘肃兰州 730030;
4. 西北民族大学甘肃省口腔疾病研究重点实验室/培育基地, 甘肃兰州 730030

收稿日期:2018-01-17 修回日期:2018-03-08 出版日期:2018-03-30 发布日期:2018-03-30
通讯作者: 谢富强,E-mail:xiefq@lzu.edu.cn E-mail:xiefq@lzu.edu.cn
作者简介:李杨,E-mail:liyang2015@lzu.edu.cn;邢龙,E-mail:499768964@qq.com
基金资助:
西北民族大学引进人才科研项目（XbMuyjrc201319）

Clinicopathological significance of expression of thioredoxin and its reductase-1 in tongue squamous cell carcinoma

LI Yang^1,2, XING Long^3,4, MOHAMMED H^1,2, MA Xiaolong^1,2, XIE Fuqiang^1,2, FENG Zhenghu^3,4, CHE Yinfu¹

1. School of Stomatology, Lanzhou University, Lanzhou 730000;
2. The Second Hospital of Lanzhou University, Lanzhou 730000;
3. Key Lab of Stomatology of State Ethnic Affairs Commission, Northwest Minzu University, Lanzhou 730030;
4. Key Lab of Oral Diseases of Gansu Province, Northwest Minzu University, Lanzhou 730030, Gansu, China

Received:2018-01-17 Revised:2018-03-08 Online:2018-03-30 Published:2018-03-30

摘要/Abstract

摘要： 目的：研究硫氧还蛋白（Trx）和硫氧还蛋白还原酶-1（TrxR1）在舌鳞癌组织中的表达及其临床意义。方法：收集28例舌鳞癌组织和10例癌旁上皮组织，采用免疫组织化学SP三步法检测Trx和TrxR1蛋白在两种组织中的表达水平，并分析其表达与临床病理特征的关系。结果：舌鳞状细胞癌组织中的Trx和TrxR1蛋白表达水平明显高于癌旁正常上皮组织，癌组织和癌旁正常组织的Trx IOD值分别为（2.84±0.34）×10⁸和（3.91±3.00）×10⁷（P < 0.01），TrxR1 IOD分别为（1.88±0.29）×10⁸和（0.69±0.32）×10⁷（P < 0.05）；Trx和TrxR1蛋白表达水平在不同肿瘤大小、分化程度组间表达的差异均具有统计学意义（P均 < 0.05）；Trx和TrxR1表达水平之间呈正相关关系（r=0.504，P < 0.05），且Trx和TrxR1高表达组与低表达组的生存率差异具有统计学意义（P < 0.05）。结论：硫氧还蛋白及其还原酶-1可能为舌鳞状细胞癌的药物治疗靶点和早期诊断、肿瘤筛查的重要临床指标。

关键词: 舌鳞状细胞癌, 硫氧还蛋白, 硫氧还蛋白还原酶-1, 免疫组织化学

Abstract: OBJECTIVE: To study the expression and clinical significance of thioredoxin (Trx) and thioredoxin reductase-1 (TrxR1) in tongue squamous cell carcinoma. METHODS: Twenty-eight cases of tongue squamous cell carcinoma and 10 cases of normal epithelial tissues were collected. Expression levels of Trx and TrxR1 in two tissues were detected by the SP immunohistochemical three-step method. The relationship between their expression and clinicopathological features was analyzed. RESULTS: The expression levels of Trx and TrxR1 in tongue squamous cell carcinoma tissues were significantly higher than those in adjacent normal epithelial tissues. Trx IOD values in cancer tissues and adjacent normal tissues were (2.84±0.34)×10⁸ and (3.91±3.00)×10⁷,respectively (P < 0.01). TrxR1 IOD was (1.88±0.29)×10⁸ and (0.69±0.32)×10⁷ (P < 0.05). Trx and TrxR1 protein expression levels were between tumor size and differentiation;the differences in expression were statistically significant (P < 0.05). The expression levels of Trx and TrxR1 were moderately correlated (r=0.504,P < 0.05),and the high and low expression groups of Trx and TrxR1 were expressed. The difference in survival was statistically significant (P < 0.05). CONCLUSION: Thioredoxin and its reductase-1 can possibly be targets of drug therapy for tongue squamous cell carcinoma and important clinical indicators for early diagnosis and tumor screening.

Key words: tongue squamous cell carcinoma, thioredoxin, thioredoxin reductase-1, immunohistochemistry

中图分类号:

R780.2

李杨, 邢龙, MOHAMMED H, 马小龙, 谢富强, 冯正虎, 车银富. 舌鳞状细胞癌组织中硫氧还蛋白和硫氧还蛋白还原酶-1的表达及其意义[J]. 癌变·畸变·突变, 2018, 30(2): 87-91.

LI Yang, XING Long, MOHAMMED H, MA Xiaolong, XIE Fuqiang, FENG Zhenghu, CHE Yinfu. Clinicopathological significance of expression of thioredoxin and its reductase-1 in tongue squamous cell carcinoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(2): 87-91.

参考文献

[1] LI Y D,MA X,HAN Y L,et al. Clinical features of multiple primary carcinomas of the oral cavity[J]. Exp Ther Med,2017,13(2):634-638.
[2] CUSUMANO R J,PERSKY M S. Squamous cell carcinoma of the oral cavity and oropharynx in young adults[J]. Head Neck Surg,1988,10(4):229.
[3] OKUBO M,IWAI T,NAKASHIMA H,et al. Squamous cell carcinoma of the tongue dorsum:incidence and treatment considerations[J]. Indian J Otolaryngol Head Neck Surg,2017:1-5.
[4] MATSUZAWA A. Thioredoxin and redox signaling:roles of the thioredoxin system in control of cell fate[J]. Arch Biochem Biophys,2016,617:101-105.
[5] ARNER E S,HOLMGREN A. The thioredoxin system in cancer[J]. Semin Cancer Biol,2006,16(6):420-426.
[6] GHANTOUS Y,ABU E I. Global incidence and risk factors of oral cancer[J]. Harefuah,2017,156(10):645-649.
[7] JEON J H,KIM M G,PARK J Y,et al. Analysis of the outcome of young age tongue squamous cell carcinoma[J]. Maxillofac Plast Reconstr Surg,2017,39(1):41.
[8] DHANUTHAI K,ROJANAWATSIRIVEJ S,THOSAPORN W,et al. Oral cancer:A multicenter study[J]. Med Oral Patol Oral Cir Bucal,2018,23(1):23.
[9] CARIATI P,CABELLO A S,FERNANDEZ J S,et al. Distribution of cervical metastasis in tongue cancer:Are occult metastases predictable? A retrospective study of 117 oral tongue carcinomas[J]. J Craniomaxillofac Surg,2018,46(1):155-161.
[10] 吴怡春,禇美芬,郭剑民,等. 硫氧还蛋白-1在胃癌中表达及意义[J]. 中国卫生检验杂志,2011(10):2460-2462.
[11] 兰康云,陈小燕,刘琴,等. 硫氧还蛋白与β-联蛋白在宫颈鳞状细胞癌组织高表达与恶性程度相关[J]. 细胞与分子免疫学杂志,2017,33(3):376-379.
[12] HUANG W,NIE W,ZHANG W,et al. The expression status of TRX,AR,and cyclin D1 correlates with clinicopathological characteristics and ER status in breast cancer[J]. Oncol Targets Ther,2016,9(1):4377.
[13] ZOU P,XIA Y,JI J,et al. Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer[J]. Cancer Lett,2016,375(1):114-126.
[14] ESEN H,FEYZIOGLU B,ERDI F,et al. High thioredoxin reductase 1 expression in meningiomas undergoing malignant progression[J]. Brain Tumor Pathol,2015,32(3):195-201.
[15] ZHU X,HUANG C,PENG B. Overexpression of thioredoxin system proteins predicts poor prognosis in patients with squamous cell carcinoma of the tongue[J]. Oral Oncol,2011,47(7):609-614.
[16] HAN M. Oral health status and behavior among cancer survivors in Korea using nationwide survey[J]. Int J Environ Res Public Health,2017,15(1):14.
[17] ERDI F,KAYA B,ESEN H,et al. New clues in the malignant progression of glioblastoma:can the thioredoxin system play a role?[J]. Turk Neurosurg,2018,28(1):7-12.
[18] ESEN H,ERDI F,KAYA B,et al. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades[J]. J Neurooncol,2015,121(3):451-458.
[19] JIN R,GAO Y,ZHANG S,et al. Trx1/TrxR1 system regulates post-selected DP thymocytes survival by modulating ASK1-JNK/p38 MAPK activities[J]. Immunol Cell Biol,2015,93(8):744.
[20] 于萍,步宏,王华,等. 免疫组化结果的图像分析与人工计数方法的对比研究[J]. 生物医学工程学杂志,2003,20(2):288-290.
[21] 刘保魁,杨玉秀,韩双印,等. 血浆硫氧还蛋白对肝癌的诊断价值研究[J]. 中国全科医学,2013,16(18):1578-1580.
[22] FU Y,YANG N,LI Y,et al. Evaluation of thioredoxin reductase as a novel biomarker in the diagnosis and treatment of breast cancer[J]. J Chin Pharm Sci,2014,23(10):711-715.

舌鳞状细胞癌组织中硫氧还蛋白和硫氧还蛋白还原酶-1的表达及其意义

Clinicopathological significance of expression of thioredoxin and its reductase-1 in tongue squamous cell carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[2]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[3]	杨修远, 潘月龙. CD10蛋白在结直肠癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 344-349.
[4]	杨兴肖, 邹乃祎, 李巧芳, 张雪原, 宋姮, 刘志坤, 马鸣, 单保恩, 祝淑钗. RNF2和PCNA在食管鳞状细胞癌中的表达及临床意义[J]. 癌变·畸变·突变, 2018, 30(4): 254-257.
[5]	邢龙, 李杨, 马小龙, MOHAMMED H, 黄莹, 谢富强, 冯正虎. 抗肿瘤新药乙烷硒啉对人舌鳞状细胞癌细胞增殖和迁移的影响[J]. 癌变·畸变·突变, 2018, 30(4): 279-285.
[6]	高延晓, 田梅, 高刚, 刘建香. 降扎乡高氡温泉周围居民血浆中8-羟基脱氧鸟苷和硫氧还蛋白还原酶水平的研究[J]. 癌变·畸变·突变, 2018, 30(3): 226-229.
[7]	杨修远, 潘月龙. CD10蛋白在肿瘤中的表达及其临床意义的研究进展[J]. 癌变·畸变·突变, 2017, 29(5): 397-401.
[8]	马焜, 吴昊宇, 李鹏, 王丽, 李百祥. 阿特拉津对青春期大鼠黑质区多巴胺能神经元的损伤作用[J]. 癌变·畸变·突变, 2017, 29(4): 251-255.
[9]	冯水土, 陈毅德, 陈玉强, 林雨标, 郑文慧. Gadd45α在不同幽门螺杆菌感染状态胃癌中的差异表达及临床意义[J]. 癌变·畸变·突变, 2016, 28(5): 353-358,392.
[10]	翟晓然, 江妹, 赵晓婷, 顾勐, 岳文涛. PFTK1在人非小细胞肺癌中的表达及临床意义[J]. 癌变·畸变·突变, 2016, 28(3): 231-235.
[11]	陈广灿, 洪良利, 黄杰雄, 谢澳斯, 郭丹, 刘淑慧. 广东潮汕贲门癌组织中GST-π和P-gp的表达及其临床病理意义[J]. 癌变·畸变·突变, 2016, 28(1): 36-40.
[12]	方少斌, 邓小玲, 陈筠, 陈永辉, 许铭炎. 整合素αvβ6和JunB在口腔鳞癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2015, 27(3): 234-238,241.
[13]	王媛媛，邱晓阳，况丽平，吴智勇，姚晓东，杜则澎，王少洪，沈金辉. CD44v6和Ezrin与大肠腺瘤癌变及预后的关系[J]. 癌变·畸变·突变, 2015, 27(1): 35-38.
[14]	张钧，孔洁，张安度，孔德友，张舰. 食管鳞癌组织中Nrf2和Bcl-2蛋白表达的关系及其临床意义[J]. 癌变·畸变·突变, 2014, 26(6): 419-422.
[15]	孙国贵，付占昭，杨从容，李成林，胡万宁. 鼻咽癌中EMP1蛋白的表达及其临床意义[J]. 癌变·畸变·突变, 2014, 26(4): 301-304.